出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/06/18 10:46:06」(JST)
Tenofovir (top) and tenofovir disoproxil fumarate (bottom)
|
|
Systematic (IUPAC) name | |
---|---|
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid | |
Clinical data | |
Trade names | Viread |
AHFS/Drugs.com | monograph |
MedlinePlus | a602018 |
Pregnancy cat. | B3 (AU) B (US) |
Legal status | Prescription Only (S4) (AU) ℞-only (CA) POM (UK) ℞-only (US) |
Routes | Oral |
Pharmacokinetic data | |
Bioavailability | 25% |
Protein binding | < 1% |
Half-life | 17 hours |
Excretion | Renal |
Identifiers | |
CAS number | 147127-20-6 Y |
ATC code | J05AF07 |
PubChem | CID 464205 |
DrugBank | DB00300 |
ChemSpider | 408154 Y |
UNII | 99YXE507IL Y |
KEGG | D01982 Y |
ChEMBL | CHEMBL483 Y |
NIAID ChemDB | 080741 |
Chemical data | |
Formula | C9H14N5O4P |
Mol. mass | 287.213 g/mol |
SMILES
|
|
InChI
|
|
Y (what is this?) (verify) |
Tenofovir disoproxil fumarate (TDF or PMPA[1]), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NRTIs), which block reverse transcriptase, a crucial virus enzyme in human immunodeficiency virus 1 (HIV-1) and hepatitis B virus infections.[2]
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[3]
A Cochrane review examined the use of tenofovir as a pre-exposure prophylaxis against HIV infection. It found that both tenofovir alone, as well as the tenofovir/emtricitabine combination, significantly decreased the risk of contracting HIV.[4]
The American Centers for Disease Control and Prevention (CDC) conducted a study in partnership with the Thailand Ministry of Public Health to ascertain the effectiveness of providing people who inject drugs illicitly with daily doses of the anti-retroviral drug Tenofovir as a prevention measure. The results of the study were released in mid-June 2013 and revealed a 48.9% reduced incidence of the virus among the group of subjects who received the drug, in comparison to the control group who received a placebo. The Principal Investigator of the study stated in the Lancet medical journal: “We now know that pre-exposure prophylaxis can be a potentially vital option for HIV prevention in people at very high risk for infection, whether through sexual transmission or injecting drug use.”[5]
The most common side effects associated with tenofovir include nausea, vomiting, diarrhea, and asthenia. Less frequent side effects include hepatotoxicity, abdominal pain, and flatulence.[6] Tenofovir has also been implicated in causing renal toxicity, particularly at elevated concentrations.[7]
Tenofovir can cause acute renal failure, Fanconi syndrome, proteinuria or tubular necrosis. These side effects are due to accumulation of the drug in proximal tubules. Tenofovir can interact with didanosine by increasing didanosine's concentration. It also decreases the concentration of atazanavir sulfate.
Tenofovir was initially synthesized by Antonín Holý at the Institute of Organic Chemistry and Biochemistry (IOCB), Academy of Sciences of the Czech Republic (AS CR) in Prague. The patent[8] filed by Holý in 1985, makes no mention of the potential use of the compound for the treatment of HIV infection, which had only been discovered 2 years earlier. The only antiviral application of tenofovir described in the patent is its potential for use in the treatment of herpes simplex infections.
In 1993 Erik De Clercq and other researchers at the Rega Institute for Medical Research described the activity of tenofovir against HIV in cell culture. Shortly thereafter, a collaboration was initiated with the biotechnology company Gilead Sciences to investigate tenofovir's potential as a treatment for HIV infected patients. In 1997 researchers from Gilead and the University of California, San Francisco demonstrated that tenofovir exhibits anti-HIV effects in humans when dosed by subcutaneous injection.[9]
The initial form of tenofovir used in these studies had limited potential for widespread use because it was not absorbed when administered orally. A medicinal chemistry team at Gilead developed a modified version of tenofovir, tenofovir disoproxil fumarate.[10] This version of tenofovir, which is the only version used clinically today, is often referred to simply as "tenofovir". In this version of the drug, the two negative charges of the tenofovir phosphonic acid group are masked, thus enhancing oral absorption.
Tenofovir disoproxil fumarate was approved by the U.S. Food and Drug Administration (FDA) on October 26, 2001 for the treatment of HIV, and on August 11, 2008 for the treatment of chronic hepatitis B.[11][12]
Tenofovir disoproxil fumarate is a prodrug form of tenofovir. It is also marketed under the brand name Reviro by DRL. Tenofovir is also available in a fixed-dose combination with emtricitabine in a product with the brand name Truvada for once-a-day dosing. Atripla, a fixed-dose triple combination of tenofovir, emtricitabine and efavirenz, was approved by the FDA on 12 July 2006 and is now available, providing a single daily dose for the treatment of HIV.
A difficult step in the manufacture of tenofovir is near the end, when the mixture is "like oatmeal, making it very difficult to stir," said Joseph Fortunak, who left Abbott Laboratories to teach at Howard. That slows the next reaction, a problem because the intermediary is highly unstable and decomposes, thus lowering the yield.
A catalyst, TBAB (tetrabutylammonium bromide) sped up the reaction and thinned the oatmeal-like mixture into something "like milk," Williams said. But unexpectedly, it made the product more stable, which substantially increased the yield. This lowered the cost by about 20%.[13]
Tenofovir may be measured in plasma by liquid chromatography. Such testing is useful for monitoring therapy and to prevent drug accumulation and toxicity in patients with renal or hepatic impairment.[14][15][16]
|
|
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
リンク元 | 「テノホビル」「TDF」 |
拡張検索 | 「tenofovir disoproxil fumarate」「tenofovir disoproxil」「tenofovir alafenamide fumarate」 |
.